董明珠没有再担任格力电器的总裁，以张伟为首的格力年轻化管理团队走上前台。 格力电器如何推进管理层的年轻化，成为投资者关心的热点之一。董明珠回应称，格力重视人才培养，不是以年龄、资历来衡量，关键在于人才的思想要保 持年轻化，有创新能力、责任心及敢于拼搏。 "绝不用海归派，只在国内高校里培养自己的人才。" 此次换届，格力电器形成以董明珠领衔的老、中、青结合的董事会，以及由张伟带队的年轻化的管理团队。其中，技术出身的格力电器新晋非独立董事钟成 堡较受瞩目，他2008年从哈工大本科毕业后加入格力，历任技术员、技术研究组组长、研究所所长、研究院院长，他2024年在北京理工大学获得硕士学位。 他现任格力电器总工程师、总裁助理，是格力智能装备业务的负责人。 与竞争对手美的集团通过收购德国库卡集团进入机器人与自动化领域不同，格力电器发展智能装备、工业机器人业务，坚持走自主创新的道路。 4月22日，格力电器（000651.SZ）临时股东大会审议通过了公司董事会换届选举的议案，董明珠顺利当选新一届董事，并再次当选格力电器董事长，开启她 执掌格力电器的第五个三年任期。值得关注的是，她没有再担任格力电器的总裁。 22日晚，格力电器公 ...

业绩稳定增长，盈利能力持续提升 杭叉集团2024年实现营业收入164.9亿元，同比增长1.15%（调整后）；归母净利润20.2亿元，同比增长 17.9%（调整后）。毛利率为23.6%，同比上升2.8个百分点；净利率为13.1%，同比上升1.8个百分点。 公司2025年一季度实现营业收入45.1亿元，同比增长8.0%；归母净利润4.4亿元，同比增长15.2%。毛利率 为20.5%，同比下降0.1个百分点；净利率为10.0%，同比上升0.4个百分点。 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客 户，用作新媒体形势下研究信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿 订阅、接收或使用本订阅号中的任何信息。本订阅号难以设置访问权限，若给您造成不便， 敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相关人员为光大 证券的客户。 报告摘要 本订阅号是光大证券股份有限公司研究所（以下简称"光大证券研究所"）依法设立、独立运营的 官方唯一订阅号。其他任何以光大证券研究所名义注册的、或含有"光大证券研究"、与光大证券 研究 ...

贯彻高质量发展，利润、现金流各项财务指标表现优异营收端：实现稳健增长，海外占比提升至64%。 2024 年公司营收777.73 亿元，同比+6.22%；其中Q4 营业收入198.83 亿元，同比+12.49%，2024 年下半 年海外市场增速复苏，四季度营收增速优于全年。 1）全年分市场来看，海外营收占主营收入比重提升至64%。国内273.18 亿元，同比-3.35%，其中挖掘 机械实现正增长，非挖仍有下滑；海外485.13 亿元，同比+12.15%，维持较好增长，海外营收在主营业 务收入占比已达64%，同比+3.5pct，海外细分地区来看，亚澳205.7 亿元，同比+15.47%；欧洲123.2 亿 元，同比+1.86%；美洲102.8 亿元，同比+6.64%；非洲区域53.5 亿元，同比+44.02%，新兴市场总体表 现更好。 事件 2024 年营业收入777.73 亿元，同比增加6.22%；归母净利润59. 75亿元，同比增加31.98%。单季度表现 来看，Q4 营业收入198. 83亿元，同比增加12.49%；归母净利润11.07 亿元， 同比增加141.15%。 简评 预计公司2025-2027年实 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [11]. Core Views - The company, as a leading manufacturer in China's construction machinery industry, is expected to undergo a value reassessment in the new cycle, driven by internationalization, product expansion, and improved operational quality [3][6]. - The current upward trend in both domestic and overseas construction machinery markets supports the company's potential for value reassessment during the new upward cycle [9]. Summary by Sections Introduction - The report discusses the value reassessment of the company in the context of a new cycle, emphasizing the importance of demand-side analysis and the company's operational quality, product line expansion, and business layout [6][18]. Industry Trends - The domestic market is at the beginning of a new upward cycle, with significant growth in excavator sales, which increased by 38.3% year-on-year in Q1 2025 [7][21]. - The global market for construction machinery presents vast opportunities, with emerging markets showing sustained demand growth [48][49]. Company Analysis - The company is enhancing its international presence, with overseas revenue contributing 44% and gross profit contributing 47% in H1 2024 [8][9]. - Product line expansion includes strengthening its excavator business and increasing its presence in the mining machinery sector, which is expected to drive revenue and profit growth [8][9]. - Operational quality is improving, with anticipated increases in profitability and asset quality due to scale effects and a shift towards high-margin overseas revenue [9][9]. Investment Recommendations - The company is projected to achieve a net profit of 6.124 billion and 8.224 billion yuan in 2024 and 2025, respectively, with corresponding price-to-earnings ratios of 17 times and 12 times [9].

Core Viewpoint - The Chinese dairy industry is in an adjustment period in 2024, facing challenges such as excess raw milk supply, sluggish consumption growth, and intensified competition, while also presenting opportunities through product structure adjustments, overseas market expansion, and cost optimization [3] Group 1: Company Performance - Ausnutria reported both revenue and net profit growth, showcasing the resilience of Chinese dairy companies and providing a reference model for the industry to navigate through cycles [3] - The self-owned brand milk powder segment achieved total revenue of approximately 5.806 billion yuan, with goat milk powder revenue at 3.699 billion yuan, a year-on-year increase of 12.7% [4] - The nutrition products segment generated revenue of about 305 million yuan, with a year-on-year growth of 7.1%, and the NC brand saw revenue of approximately 176 million yuan, up 29% [8] Group 2: International Expansion - Ausnutria's international strategy is highlighted by significant revenue growth in its international goat milk powder business, which reached 647 million yuan, a substantial increase of 68.2% [4] - The company has accelerated its global market expansion, with notable entries into the U.S. market and continued growth in the Middle East and CIS regions [4][6] - Ausnutria's international operations are supported by investments in new facilities, such as the Pallas factory in the Netherlands, and the acquisition of the remaining 50% stake in Amalthea Group B.V. [7] Group 3: Technological Innovation - The company emphasizes technological innovation as a key driver for high-quality development, with advancements in product development and a focus on precision and functionality in the global nutrition market [8] - Ausnutria has established a comprehensive evaluation system for its research and development processes and has launched a lifecycle management platform to enhance R&D efficiency [9] - The company has applied for 529 patents and registered 3,601 trademarks, reflecting its commitment to innovation and intellectual property [9] Group 4: Product Development - Ausnutria launched several new products, including four goat milk infant formula products and three children's and adult goat milk products, enhancing its product matrix [11] - The company is focusing on differentiated consumer needs across all age groups with its NC brand, introducing new functional products to accelerate its presence in the precision nutrition market [11] - The introduction of local products, such as goat cheese in the Middle East, demonstrates Ausnutria's strategy to meet diverse consumer demands and build competitive advantages [6] Group 5: Future Strategy - Ausnutria plans to maintain its strategic direction focused on consumer needs, strengthening its core business and brand while leveraging its full industry chain advantages in nutrition products [13] - The company aims to accelerate its international market expansion as part of its globalization strategy [13]

"买买买"战略下，安踏集团再下一城。4月10日，安踏集团宣布将全资收购起源于德国的户外服饰、鞋履及装备专业品牌Jack Wolfskin（狼爪），基础对价 为现金2.9亿美元。在满足其他惯常交割条件后，本次收购预计将于2025年二季末或三季初完成。 狼爪成立于1981年，总部位于德国伊德斯坦因（Idstein），从狼爪旗舰店来看，大部分冲锋衣单价在500—1500元之间，定位中高端户外市场，应用场景涵 盖徒步、自行车、滑雪以及露营等。 对于此次收购，安踏集团董事局主席丁世忠表示："安踏集团始终坚持'单聚焦、多品牌、全球化'战略不动摇。我们很期待狼爪品牌能够加入安踏集团多品 牌矩阵，强化集团在户外运动赛道的纵深布局。" 近两年，安踏集团一直在通过"买买买"战略来丰富自己的品牌阵容。如在2015年收购了在俄罗斯以及东欧市场的运动休闲品牌Sprandi（斯潘迪）；2016年以 1.5亿元与DESCENTE（迪桑特）子公司和伊藤忠公司成立合资业务，收购迪桑特在中国区独家经营、产品设计、销售及分销的业务；2017年收购韩国高端 户外品牌KOLON SPORT（可隆），同样也是成立合资企业，负责中国市场的运营和销售；20 ...

近日，广西柳工机械股份有限公司正式披露2024年年度报告，数据显示，公司在过去一年成绩斐然。 2024年柳工实现营业收入约300.63亿元，同比增长9.24%， 这一增速创历史新高 ；归属于上市公司股东的净利润约13.27亿元，同比大幅增长52.92%。 图：柳工2024年度财务指标 在国内房地产市场持续调整、工程机械行业整体处于周期底部修复阶段的大背景下，柳工凭借 加速出海与国内业务变革驱动 ， 实现营收与净利双增长 ，国际化与 电动化成为其高质量发展的核心动力。 当前， 工程机械行业面临诸多挑战 。受有效需求不足影响，本轮下行周期触底后，行业总销量仍处于低位。房地产及基建需求端改善不明显，更新换代需求有 限，同时出口量及出口金额增速进一步放缓，行业在周期底部艰难修复。2024年下半年以来，新增专项债发行放量、万亿国债落地，部分地区项目开工情况好转， 再加上大规模设备更新政策推出以及低基数效应，市场开始逐步恢复。 在这样的行业环境中， 柳工国内业务变革成效显著。 自混改以来，柳工国内营销大力开展质量、效率、动力变革，敏锐捕捉市场周期调整机遇。各产品线全面跑 赢行业，装载机继续保持龙头优势，挖掘机实现快速增长 ...

Core Viewpoint - The article emphasizes the characteristics that high-quality Chinese assets should possess, highlighting Guizhou Moutai's strong performance as a benchmark for investor confidence in a volatile global market [1][8]. Financial Performance - In 2024, Guizhou Moutai achieved total revenue of 170.9 billion yuan, a year-on-year increase of 15.71%, and a net profit attributable to shareholders of 86.228 billion yuan, up 15.38% year-on-year [1][2]. - The company plans to distribute a cash dividend of 276.24 yuan per 10 shares, totaling 34.671 billion yuan, which represents 75% of the net profit attributable to shareholders [2][3]. Product Performance - Moutai liquor generated revenue of 145.928 billion yuan in 2024, reflecting a 15.28% increase, while other series of liquor achieved 24.684 billion yuan, growing by 19.65% [3]. - The core product, Moutai liquor, continues to show stable revenue growth, while other series are emerging as new growth engines for the company [2][3]. Channel Optimization - Guizhou Moutai has developed a diversified sales channel system, with direct sales revenue reaching 74.843 billion yuan, an increase of 11.32% [4]. - The "i Moutai" digital marketing platform generated 20.024 billion yuan in revenue, enhancing consumer interaction and brand loyalty [4]. Brand Value and Internationalization - In 2024, Guizhou Moutai's brand value reached 87.298 billion USD, ranking first among liquor brands in the Kantar "BrandZ Most Valuable Chinese Brands" list [5]. - The company has accelerated its internationalization efforts, achieving over 5 billion yuan in export revenue for the first time, with high-value Moutai liquor exports increasing by over 40% [6][7]. Cultural Promotion - Guizhou Moutai has engaged in extensive cultural promotion activities, hosting 225 tasting events and attracting over 15,000 participants [6]. - The company has established a systematic approach to cultural branding, enhancing its international recognition and influence [7]. Overall Impact - Guizhou Moutai's strong financial performance, high dividend payouts, and effective brand and channel strategies collectively reinforce its position as a high-quality asset in the market, contributing to the overall development of the liquor industry [8].

Core Viewpoint - Heng Rui Medicine has made significant personnel changes following the impressive performance in its 2024 annual report, emphasizing its commitment to technological innovation and internationalization as core strategies [1][6]. Financial Performance - In 2024, Heng Rui Medicine reported a record revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit attributable to shareholders of 6.337 billion yuan, up 47.28% [2]. - The sales revenue from innovative drugs reached 13.892 billion yuan, accounting for over half of the company's total sales revenue, with a year-on-year growth of 30.6% despite increasing competition and pricing pressures [2]. - The company invested 8.228 billion yuan in research and development, with 6.583 billion yuan classified as expense-based R&D, representing 29.4% of total sales revenue [2]. Research and Development - Heng Rui Medicine has 14 complementary R&D centers across China, Japan, the United States, Australia, and Switzerland, with a global R&D team of over 5,500 people [2]. - The company has 90+ innovative products in clinical development and approximately 400 clinical trials ongoing domestically and internationally, ranking 8th in the global TOP25 pipeline scale pharmaceutical companies list by Citeline [4]. Strategic Partnerships and Licensing - Heng Rui Medicine has granted exclusive rights for the development, production, and commercialization of its GLP-1 class innovative drug and DLL3 ADC innovative drug to U.S. companies Kailera Therapeutics and IDEAYA Biosciences, respectively [3]. - The company entered into an agreement with Merck to license an oral small molecule project, receiving an upfront payment of 200 million USD and potential milestone payments up to 1.77 billion USD, along with possible sales royalties [4]. Talent Acquisition and Management - The company has intensified talent acquisition efforts, bringing in over 700 core talents in 2024, including more than 200 with doctoral degrees [6]. - Heng Rui Medicine is actively promoting internal talent development through various programs aimed at nurturing high-potential talents and enhancing management capabilities [6]. Market Focus - While Heng Rui Medicine has traditionally focused on oncology, it is expanding its research pipeline in metabolic, autoimmune, and other chronic disease areas, with 47 innovative pipelines in non-oncology fields now surpassing those in oncology [6].

据上海证券报记者统计，截至4月2日晚，A股共有35家食品饮料公司发布了2024年年报。从业绩表现来 看，休闲食品、运动饮料等细分行业表现亮眼，多家公司业绩增长。整体而言，龙头公司韧性更强。尽 管白酒行业处于深度调整中，但贵州茅台依然保持了15%以上的净利润增速，继续稳健增长。 食品饮料公司向来是高分红的"常客"，每年的年报分红都备受投资者期待。据记者统计，35家公司中， 除5家公司因年度亏损或累计可分配利润为负外，其余公司均拟进行年度现金分红，累计现金分红比例 （不含回购）超60%的有21家。 近年来，渠道端的剧烈变化给食品饮料行业带来挑战的同时，也带来机遇。从年报来看，抓住会员制超 市、零食量贩店、社交电商等新兴渠道增长红利的公司，业绩普遍较好。同时，在国内市场趋于饱和的 背景下，一批公司奋力拓展海外市场，2024年取得积极成效。 主营泡椒凤爪的有友食品在2024年年报中表示，在传统零售渠道持续萎缩的行业变局中，公司实现结构 性突围，开创性突破会员制零售体系，建立与头部渠道的合作；深化主流零食量贩渠道渗透，夯实线下 布局；加速电商运营模式迭代，通过社交电商全域运营实现线上销售额倍增。 2022年和2023年 ...